martedì, 21 marzo 2023
28 Settembre 2018

FDA Approves Duvelisib for CLL and Follicular Lymphoma

September 24, 2018 – The FDA has approved duvelisib for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or relapsed/refractory follicular lymphoma. The CLL/SLL indication is a standard approval and the follicular lymphoma indication is an accelerated approval contingent on the results of a confirmatory trial. Both indications are for the treatment of patients who have received at least … (leggi tutto)